TY  - JOUR
A1  - Dohna, Martha Anna
A1  - Renz, Diane Miriam Esther
A1  - Stehling, Florian
A1  - Dohna-Schwake, Christian
A1  - Sutharsan, Sivagurunathan
A1  - Neurohr, Claus
A1  - Wirtz, Hubert
A1  - Eickmeier, Olaf
A1  - Große-Onnebrink, Jörg
A1  - Sauerbrey, Axel
A1  - Soditt, Volker
A1  - Poplawska, Krystyna
A1  - Wacker, Frank
A1  - Johannes Montag, Michael
T1  - Coil embolisation for massive haemoptysis in cystic fibrosis
T2  - BMJ Open Respiratory Research
N2  - Introduction Massive haemoptysis is a life-threatening event in advanced cystic fibrosis (CF) lung disease with bronchial artery embolisation (BAE) as standard of care treatment. The aim of our study was to scrutinise short-term and long-term outcomes of patients with CF and haemoptysis after BAE using coils.

Methods We carried out a retrospective cohort study of 34 adult patients treated for massive haemoptysis with super selective bronchial artery coil embolisation (ssBACE) between January 2008 and February 2015. Embolisation protocol was restricted to the culprit vessel(s) and three lobes maximum. Demographic data, functional end-expiratory volume in 1 s in % predicted (FEV1% pred.) and body mass index before and after ssBACE, sputum colonisation, procedural data, time to transplant and time to death were documented.

Results Patients treated with ssBACE showed significant improvement of FEV1% pred. after embolisation (p=0.004) with 72.8% alive 5 years post-ssBACE. Mean age of the patients was 29.9 years (±7.7). Mean FEV1% pred. was 45.7% (±20.1). Median survival to follow-up was 75 months (0–125). Severe complication rate was 0%, recanalisation rate 8.8% and 5-year-reintervention rate 58.8%. Chronic infection with Pseudomonas aeruginosa was found in 79.4%, Staphylococcus areus in 50% and Aspergillus fumigatus in 47.1%.

Discussion ssBACE is a safe and effective treatment for massive haemoptysis in patients with CF with good results for controlling haemostasis and excellent short-term and long-term survival, especially in severely affected patients with FEV<40% pred. We think the data of our study support the use of coils and a protocol of careful and prudent embolisation.
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/80246
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-802461
SN  - 2052-4439
VL  - 8
IS  - 1, art. e000985
SP  - 1
EP  - 7
PB  - BMJ Publishing Group
CY  - London
ER  -